Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2019, Article ID 4621416, 11 pages
https://doi.org/10.1155/2019/4621416
Research Article

Management of Adult Patients with Primary Immune Thrombocytopenia (ITP) in Clinical Practice: A Consensus Approach of the Spanish ITP Expert Group

1Service of Hematology, Hospital Virgen del Rocio, Sevilla, Spain
2Service of Hematology, Hospital Universitario La Paz, Madrid, Spain
3Service of Hematology, Complejo Hospitalario Universitario Insular Materno-Infantil, Las Palmas de Gran Canaria, Spain
4Service of Hematology, Hospital Universitario de Burgos, Burgos, Spain
5Service of Hematology and Hemotherapy, Universitario de Araba, Vitoria-Gasteiz, Álava, Spain
6Service of Hematology and Hemotherapy, Hospital Universitario y Politécnico La Fe, Valencia, Spain
7Service of Hematology and Hemotherapy, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complejo Hospitalario Universitario A Coruña, A Coruña, Spain
8Department of Hematology and Medical Oncology, Hospital General Universitario Morales Meseguer, IMIB-Arrixaca, CIBERER, Murcia, Spain
9Service of Clinical Hematology, Hospital del Mar-Parc de Salut Mar, Barcelona, Spain
10Hematopoietic Stem Cell Transplantation Unit, Hospital Universitario Vall d’Hebron, Barcelona, Spain
11Service of Hematology, Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain

Correspondence should be addressed to M. Eva Mingot-Castellano; moc.liamg@tognimem

Received 30 April 2019; Accepted 25 June 2019; Published 22 August 2019

Academic Editor: Shaji Kumar

Copyright © 2019 M. Eva Mingot-Castellano et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Cuker, D. B. Cines, and C. E. Neunert, “Controversies in the treatment of immune thrombocytopenia,” Current Opinion in Hematology, vol. 23, no. 5, pp. 479–485, 2016. View at Google Scholar
  2. N. Cooper, “State of the art - how I manage immune thrombocytopenia,” British Journal of Haematology, vol. 177, no. 1, pp. 39–54, 2017. View at Publisher · View at Google Scholar
  3. M. P. Lambert and T. B. Gernsheimer, “Clinical updates in adult immune thrombocytopenia,” Blood, vol. 129, no. 21, pp. 2829–2835, 2017. View at Publisher · View at Google Scholar · View at Scopus
  4. M. L. Lozano and V. Vicente, “Current treatment of primary immune thrombocytopenia,” Medicina Clínica, vol. 142, no. 9, pp. 399–405, 2014. View at Google Scholar
  5. S. Thota, G. Kistangari, H. Daw, and T. Spiro, “Immune thrombocytopenia in adults: an update,” Cleveland Clinic Journal of Medicine, vol. 79, no. 9, pp. 641–650, 2012. View at Publisher · View at Google Scholar
  6. D. Nugent, R. McMillan, J. L. Nichol, and S. J. Slichter, “Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production,” British Journal of Haematology, vol. 146, no. 6, pp. 585–596, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Stasi, “Immune thrombocytopenia: pathophysiologic and clinical update,” Seminars in Thrombosis and Hemostasis, vol. 38, no. 5, pp. 454–462, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. F. Rodeghiero, R. Stasi, T. Gernsheimer et al., “Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group,” Blood, vol. 113, no. 11, pp. 2386–2393, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Michel, “Immune thrombocytopenia nomenclature, consensus reports, and guidelines: what are the consequences for daily practice and clinical research?” Seminars in Hematology, vol. 50, Suppl 1, pp. S50–S54, 2013. View at Publisher · View at Google Scholar
  10. C. Neunert, W. Lim, M. Crowther, A. Cohen, L. Solberg Jr., and M. A. Crowther, “The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia,” Blood, vol. 117, no. 16, pp. 4190–4207, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. D. Provan, R. Stasi, A. C. Newland et al., “International consensus report on the investigation and management of primary immune thrombocytopenia,” Blood, vol. 115, no. 2, pp. 168–186, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Sanz Alonso, V. Vicente García, A. Fernández Jurado, M. López Fernández, C. Grande García, I. Jarque Ramos et al., Directrices de diagnóstico, tratamiento y seguimiento de la PTI. Documento de consenso, Soc Española Hemalogía y Hemoter Madrid Prodrug Multimed SL., 2011.
  13. D. Provan and A. C. Newland, “Current management of primary immune thrombocytopenia,” Advances in Therapy, vol. 32, no. 10, pp. 875–887, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. R. Warrier and A. Chauhan, “Management of immune thrombocytopenic purpura: An Update,” The Ochsner Journal, vol. 12, no. 3, pp. 221–227, 2012. View at Google Scholar · View at Scopus
  15. N. Vianelli, F. Palandri, N. Polverelli et al., “Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years,” Haematologica, vol. 98, no. 6, pp. 875–880, 2013. View at Publisher · View at Google Scholar
  16. M. Marangon, N. Vianelli, F. Palandri et al., “Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response,” European Journal of Haematology, vol. 98, no. 4, pp. 371–377, 2017. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Vibor, I. M. Rogulj, and S. K. Ostojic, “Is there any role for splenectomy in adulthood onset chronic immun e thrombocytopenia in the era of TPO receptors agonists? A critical overview,” Cardiovascular & Hematological Disorders-Drug Targets, vol. 17, no. 1, pp. 38–51, 2017. View at Publisher · View at Google Scholar
  18. L.-H. Thai, M. Mahévas, F. Roudot-Thoraval et al., “Long-term complications of splenectomy in adult immune thrombocytopenia,” Medicine (Baltimore), vol. 95, no. 48, Article ID e5098, 2016. View at Google Scholar · View at Scopus
  19. F. Rodeghiero, “Is ITP a thrombophilic disorder?” American Journal of Hematology, vol. 91, no. 1, pp. 39–45, 2016. View at Publisher · View at Google Scholar
  20. M. L. Lozano, N. Revilla, T. J. Gonzalez-Lopez et al., “Real-life management of primary immune thrombocytopenia (ITP) in adult patients and adherence to practice guidelines,” Annals of Hematology, vol. 95, no. 7, pp. 1089–1098, 2016. View at Publisher · View at Google Scholar
  21. M. Varela-Ruiz, L. Díaz-Bravo, and L. García-Durán, “Descripción y usos del método Dephi en investigaciones del área de la salud,” Investigación en Educación Médica, vol. 1, no. 2, pp. 90–95, 2012. View at Google Scholar
  22. J. Alcalde-Escribano, P. Ruiz-López, F. Acosta et al., “Estudio Delphi para el desarrollo de pautas de indicación de pruebas preoperatorias. Consenso de anestesiólogos y cirujanos,” Revista de Calidad Asistencial, vol. 17, no. 1, pp. 34–42, 2002. View at Publisher · View at Google Scholar
  23. P. Comet-Cortés, G. Escobar-Aguilar, T. González-Gil et al., “Establecimiento de prioridades de investigación en enfermería,” Enfermería Clínica, vol. 27, no. 6, pp. 88–96, 2010. View at Publisher · View at Google Scholar
  24. C. Besses, J. C. Hernández-Boluda, M. Pérez Encinas et al., “Current opinion and consensus statement regarding the diagnosis, prognosis, and treatment of patients with essential thrombocythemia: a survey of the Spanish Group of Ph-negative Myeloproliferative Neoplasms (GEMFIN) using the Delphi method,” Annals of Hematology, vol. 95, no. 5, pp. 719–732, 2016. View at Publisher · View at Google Scholar
  25. J. M. Raya, S. Montes-Moreno, A. Acevedo et al., “Pathology reporting of bone marrow biopsy in myelofibrosis; application of the Delphi consensus process to the development of a standardised diagnostic report,” Journal of Clinical Pathology, vol. 67, no. 7, pp. 620–625, 2014. View at Publisher · View at Google Scholar
  26. A. Iorio, E. Iserman, V. Blanchette et al., “Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement,” Haemophilia, vol. 23, no. 3, pp. e170–e179, 2017. View at Publisher · View at Google Scholar
  27. A. E. Sobota, N. Shah, and J. W. Mack, “Development of quality indicators for transition from pediatric to adult care in sickle cell disease: a modified delphi survey of adult providers,” Pediatric Blood & Cancer, vol. 64, no. 6, 2017. View at Publisher · View at Google Scholar
  28. L. Vazquez, M. Salavert, J. Gayoso, M. Lizasoain, I. Ruiz Camps, and N. Di Benedetto, “Delphi-based study and analysis of key risk factors for invasive fungal infection in haematological patients,” Revista Española de Quimioterapia, vol. 30, no. 2, pp. 103–117, 2017. View at Google Scholar
  29. C. G. Garcia, R. Martinez, and D. V. Ferreiras, “Comparison of international guidelines for primary autoimmune thrombocytopenia,” Medicina Clínica, vol. 143, no. 9, pp. 408–419, 2014. View at Google Scholar
  30. I. Pabinger, G. Gastl, M. Steurer et al., “Primary immune thrombocytopenia in adults: diagnostics and treatment consensus statement of the Austrian Society of Hematology and Oncology (OGHO),” Wiener Klinische Wochenschrift, vol. 124, no. 3-4, pp. 111–123, 2012. View at Publisher · View at Google Scholar
  31. T. Ng, A. Gatt, and M. Smith, “Primary immune thrombocytopenia in adults: clinical practice versus management guidelines,” Postgraduate Medical Journal, vol. 93, no. 1105, pp. 645-646, 2017. View at Publisher · View at Google Scholar
  32. M. Á. Sanz, V. Vicente García, A. Fernández et al., “Guidelines for diagnosis, treatment and monitoring of primary immune thrombocytopenia,” Medicina Clínica, vol. 138, no. 6, pp. 261.e1–261.e17, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Matzdorff, A. Giagounidis, A. Greinacher et al., “Diagnosis and therapy of autoimmune thrombocytopenia. Recommendations of a joint expert group of DGHO, DGTI, DTH,” Onkologie, vol. 33, Suppl 3, pp. 2–20, 2010. View at Google Scholar · View at Scopus
  34. W. Ghanima, P. A. Holme, and G. E. Tjonnfjord, “Immune thrombocytopenia- pathophysiology and treatment,” Tidsskr Nor Laegeforen, vol. 130, no. 21, pp. 2120–2123, 2010. View at Google Scholar
  35. M. Mahevas, M. Gerfaud-Valentin, G. Moulis et al., “Characteristics, outcome, and response to therapy of multirefractory chronic immune thrombocytopenia,” Blood, vol. 128, no. 12, pp. 1625–1630, 2016. View at Publisher · View at Google Scholar
  36. J. R. Gonzalez-Porras, T. J. Gonzalez López, M. T. Alvarez-Roman, C. Pascual, B. Sanchez- Gonzalez, F. Fernandez-Fuertes et al., “La respuesta duradera a eltrombopag en PTI primaria es predictor de la probabilidad de suspender con éxito eltrombopag. LIX Congreso Nacional de la Sociedad Española de Hematologia y Hemoterapia,” Haematologica, vol. 256, PC295, 2017. View at Google Scholar
  37. M. G. Mazzucconi, C. Santoro, E. Baldacci et al., “TPO-RAs in pITP: description of a case series and analysis of predictive factors for response,” European Journal of Haematology, vol. 98, no. 3, pp. 242–249, 2017. View at Publisher · View at Google Scholar
  38. A. Cuker and C. E. Neunert, “How I treat refractory immune thrombocytopenia,” Blood, vol. 128, no. 12, pp. 1547–1554, 2016. View at Publisher · View at Google Scholar